Researchers at Albert Einstein College of Medicine of Yeshiva University developed an experimental nanoparticle therapy could be used to speed the healing of all sorts of wounds, including everyday cuts and burns, surgical incisions, and chronic skin ulcers, which are a particular problem in the elderly and people with diabetes.
Details of this therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.
David J. Sharp, Ph.D., and his colleagues had earlier discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. They reasoned that the healing cells could reach their destination faster if their levels of FL2 could be reduced. So they developed a drug that inactivates the gene that makes FL2 and then put the drug in tiny gel capsules called nanoparticles and applied the nanoparticles to wounds on mice. The treated wounds healed much faster than untreated wounds. FL2 belongs to the fidgetin family of enzymes, which play varying roles in cellular development and function.
Credit: Vera DesMarais
Dr. Sharp and project co-leader developed a wound-healing therapy that uses molecules of silencing RNA (siRNAs) specific for FL2. The siRNAs act to silence genes. They do so by binding to a gene’s messenger RNA (mRNA), preventing the mRNA from being translated into proteins (in this case, the enzyme FL2). However, siRNAs on their own won’t be effectively taken up by cells, particularly inside a living organism. They will be quickly degraded unless they are put into some kind of delivery vehicle.
To find a way to deliver siRNAs for curbing FL2, they developed nanoparticles that protect molecules such as siRNA from being degraded as they ferry the molecules to their intended targets.
The nanoparticles with their siRNA cargoes were then tested by topically applying them to mice with either skin excisions or burns. In both cases, the wounds closed more than twice as fast as in untreated controls. We saw normal, well-orchestrated regeneration of tissue, including hair follicles and the skin’s supportive collagen network.
Dr. Sharp plans to start testing the therapy on pigs, whose skin closely resembles that of humans, within months.
